CH516557A - Antiphlogistic cinnamamides - Google Patents
Antiphlogistic cinnamamidesInfo
- Publication number
- CH516557A CH516557A CH1442871A CH1442871A CH516557A CH 516557 A CH516557 A CH 516557A CH 1442871 A CH1442871 A CH 1442871A CH 1442871 A CH1442871 A CH 1442871A CH 516557 A CH516557 A CH 516557A
- Authority
- CH
- Switzerland
- Prior art keywords
- formula
- sep
- acid
- radicals
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/64—Acyl halides
- C07C57/72—Acyl halides containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/56—Unsaturated compounds containing hydroxy or O-metal groups containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/224—Phosphorus triamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4056—Esters of arylalkanephosphonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/535—Organo-phosphoranes
- C07F9/5352—Phosphoranes containing the structure P=C-
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5407—Acyclic saturated phosphonium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5456—Arylalkanephosphonium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Title compounds of formula (I): (where R1 is Br or I and R2 is piperidino or morpholino), which are antiphlogistics and antipyretics, are prepared by eliminating the residues D from a compound of formula (II): (where the residues D are both OH or both acyloxy, incl. sulphonyloxy). (II; D = OH or carboxylic acyloxy) can be converted into (I) by e.g. reacting with HI at slightly elevated temperature. (II; D = sulphonyloxy can be converted into (I) by e.g. reacting with an alkali iodide.
Description
Verfahren zur Herstellung neuer Zimtsäureamide Die Erfindung betrifft ein Verfahren zur Herstellung neuer Zimtsäureamide der Formel 1
EMI0001.0001
worin R1 ein Brom- oder Jodatom und R2 einen Piperidino- oder Morpholinorest bedeuten, das dadurch gekennzeichnet ist, dass man aus einer Ver bindung der Formel 2
EMI0001.0002
worin die beiden Reste D beide Hydroxyl- oder beide Acyloxyreste, beispielsweise Sulfonyloxyreste bedeuten, die beiden Reste D abspaltet.
Dabei geht man zweckmässig so vor, dass man a) falls D für Hydroxyl- oder Acyloxygruppen steht, aus einer Verbindung der Formel 2 die Hydroxyl- oder Acyloxygruppen unter Bildung einer Doppelbindung beispielsweise durch Umsetzung mit Jodwasserstoff- säure bei leicht erhöhten Temperaturen, z.B. bei 50 C, zweckmässigerweise in einem Lösungsmittel, z.B. Eis essig, eliminiert; oder b) falls D für Sulfonyloxygruppen steht, aus einer Ver bindung der Formel 2 die entsprechenden Sulfonsäure- reste unter Bildung einer Doppelbindung durch Um setzung mit einem Alkalijodid, zweckmässigerweise in einem Lösungsmittel, z.B. in Methyläthylketon, vorzugsweise bei der Siedetemperatur des verwende ten Lösungsmittels eliminiert.
Die bei dem Verfahren verwendeten Ausgangsstoffe sind neu und lassen sich nach bekannten Methoden dar stellen.
Die Herstellung einer Dihydroxy-Verbindung der For mel 2 erfolgt beispielsweise durch Umsetzung eines ent sprechenden Zimtsäureamids mit Silberacetat und Jod in Eisessig und anschliessender Umsetzung mit methano- lischer Salzsäure.
Eine Diacyloxy- oder Disulfonyloxy-Verbindung der Formel 2 erhält man durch Umsetzung einer Dihydroxy- Verbindung der Formel 2 mit einem entsprechenden Car- bonsäureanhydrid bzw. Sulfonsäurechlorid.
Die erfindungsgemäss hergestellten neuen Zimtsäure- amide der Formel 1 besitzen wertvolle pharmakologische Eigenschaften, insbesondere eine antiphlogistische und antipyretische Wirkung.
Im Kaolin- und Carrageenin-Ödem-Test an der Ratte sind die Verbindungen der Formel 1 dem Phenylbutazon bezüglich der therapeutischen Breite überlegen.
Die nachstehenden Beispiele dienen zur näheren Er läuterung der Erfindung: <I>Beispiel 1</I> 4-Brom-zimtsäurepiperidid 0,5 g (1,5 mMol) α,ss-Dihydroxy-B-(4-bromphenyl)- -propionsäurepiperidid (Fp. 112 bis 113 C, hergestellt durch Umsetzung von 4-Brom-zimtsäurepiperidid mit Silberacetat, Jod und anschliessende Umsetzung mit me- thanolischer Salzsäure) werden in 15 ml Eisessig gelöst und mit 0,24 ml 67%iger Jodwasserstoffsäure (0,32 g = 2,5 mMol Jodwasserstoff) versetzt, wobei sich allmählich ein Niederschlag bildet. Man lässt über Nacht bei 20 C stehen und erhitzt dann 5 Stunden auf 60 C.
Das Reak- tionsgemisch wird zur Entfernung von Jod mit wässriger Natriumthiosulfatlösung versetzt und mit Chloroform ex trahiert. Nach Waschen des organischen Extraktes mit verdünnter Natronlauge, verdünnter Salzsäure und Was ser wird getrocknet und im Vakuum eingedampft. Durch Säulenchromatographie an Kieselgel (Benzon/Aceton = 3 : 1) lassen sich 30 mg (77% d.Th.) farblose Kristalle vom Fp. 130 bis 133 C isolieren.
<I>Beispiel 2</I> 4-Brom-zimtsäurepiperidid Ein Gemisch aus 1,0 g (2,4 mMol) α,ss-Diacetoxy-ss- -(4-bromphenyl)-propionsäurepiperidid (Fp. 92 bis 93 C, hergestellt aus α,ss-Dihydroxy-ss-(4-bromphenyl)-propion- säurepiperidid und Essigsäureanhydrid in Gegenwart von Pyridin), 0,46 ml 67%iger wässriger Jodwasserstoffsäure (0,62 g = 4,8 mMol Jodwasserstoff) und 20 ml Eisessig lässt man 20 Stunden bei 20 C stehen und erwärmt dann noch 5 Stunden auf 40 C. Man gibt einige ml wässrige Natriumthiosulfatlösung zu und extrahiert das Gemisch mit Chloroform.
Die Chloroformphase wird mit verdünn ter Natronlauge, verdünnter Salzsäure und Wasser gewa schen und nach dem Trocknen im Vakuum eingedampft. Mit dem Rückstand führt man eine säulenchromatogra- phische Trennung an Kieselgel durch (Benzol/Aceton = 9 : 1), wobei 100 mg (14% d.Th.) 4-Brom-zimtsäurepi- peridid vom Fp. 132 bis 133 C erhalten werden.
<I>Beispiel 3</I> 4-Brom-zimtsäurepiperidid 1,3 g (2 mMol α,ss-Di-(p-toluolsulfonyloxy)-ss-(4-brom- phenyl)-propionsäurepiperidid (Fp. 150 bis 151 C, herge stellt aus a,ss-Dihydroxy-ss-(4-brompheny)-propionsäure- piperidid und p-Tolulsulfochlorid in Gegenwart von Pyr- idin) und 1,8 g (12 mMol) Natriumjodid werden in 50 ml Methyläthylketon 16 Stunden auf 80 C erhitzt. Ent standenes Jod wird durch Schütteln mit wässriger Na- triumthiosulfatlösung reduziert.
Man dampft im Vakuum ein, gibt zum Rückstand Chloroform und Wasser, trennt die Chloroformphase im Scheidetrichter ab, wäscht sie mit verdünnter Natronlauge, verdünnter Salzsäure und Wasser, trocknet über Natriumsulfat und entfernt das Lösungsmittel im Vakuum. Der Rücksand wird aus Es sigester unter Verwendung von Aktivkohle umkristalli siert. Ausbeute: 0,45 g (76% d.Th.), Fp. 132 bis 133 C.
Analog wurden folgende Verbindungen hergestellt:
EMI0002.0019
3-Brom-zimtsäurepiperidid, <SEP> Fp. <SEP> 95 <SEP> - <SEP> 99 C
<tb> 4-Brom-zimtsäuremorpholid, <SEP> Fp. <SEP> 142 <SEP> - <SEP> 144 C
<tb> 3-Brom-zimtsäuremorpholid, <SEP> Fp. <SEP> 80 <SEP> - <SEP> 81 C
<tb> 4-Jod-zimtsäurepiperidid, <SEP> Fp. <SEP> 134 <SEP> - <SEP> 135 C
<tb> 3-Jod-zimtsäurepiperidid, <SEP> Fp. <SEP> 109 <SEP> - <SEP> 110 C
<tb> 4-Jod-zimtsäuremorpholid, <SEP> Fp. <SEP> 175 <SEP> - <SEP> 177 C
<tb> 3-Jod-zimtsäuremorpholid, <SEP> Fp. <SEP> 100 <SEP> - <SEP> 101 C Die erfindungsgemäss hergestellten Verbindungen der Formel I lassen sich nach an sich bekannten Methoden in übliche pharmazeutische Anwendungsformen, gegebe nenfalls in Kombination mit anderen Wirksubstanzen, einarbeiten.
Die Einzeldosis beträgt bei Erwachsenen 200,00 mg bis 600,00 mg, bevorzugt 300,00 mg bis 400,00 mg und die Tagesdosis 400,00 mg bis<B>1</B>200,00 mg, bevorzugt 600,00 mg bis 800,00 mg.
Process for the production of new cinnamic acid amides The invention relates to a process for the production of new cinnamic acid amides of the formula 1
EMI0001.0001
where R1 is a bromine or iodine atom and R2 is a piperidino or morpholino radical, which is characterized in that a compound of the formula 2
EMI0001.0002
where the two radicals D are both hydroxyl or both acyloxy radicals, for example sulfonyloxy radicals, the two radicals D are split off.
It is advisable to proceed in such a way that a) if D stands for hydroxyl or acyloxy groups, the hydroxyl or acyloxy groups are obtained from a compound of formula 2 with formation of a double bond, for example by reaction with hydriodic acid at slightly elevated temperatures, e.g. at 50 ° C, conveniently in a solvent, e.g. Ice vinegar, eliminated; or b) if D stands for sulfonyloxy groups, the corresponding sulfonic acid radicals from a compound of formula 2 to form a double bond by reaction with an alkali iodide, conveniently in a solvent, e.g. eliminated in methyl ethyl ketone, preferably at the boiling point of the solvent used.
The starting materials used in the process are new and can be presented using known methods.
A dihydroxy compound of formula 2 is produced, for example, by reacting a corresponding cinnamic acid amide with silver acetate and iodine in glacial acetic acid and then reacting it with methanolic hydrochloric acid.
A diacyloxy or disulfonyloxy compound of the formula 2 is obtained by reacting a dihydroxy compound of the formula 2 with a corresponding carboxylic acid anhydride or sulfonic acid chloride.
The new cinnamic acid amides of formula 1 prepared according to the invention have valuable pharmacological properties, in particular an anti-inflammatory and anti-pyretic effect.
In the kaolin and carrageenin edema test on rats, the compounds of formula 1 are superior to phenylbutazone with regard to the therapeutic range.
The following examples serve to explain the invention in more detail: <I> Example 1 </I> 4-Bromo-cinnamic acid piperidide 0.5 g (1.5 mmol) α, ss-dihydroxy-B- (4-bromophenyl) - Propionic acid piperidide (melting point 112 to 113 ° C., produced by reacting 4-bromocinnamic acid piperidide with silver acetate, iodine and subsequent reaction with methanolic hydrochloric acid) are dissolved in 15 ml of glacial acetic acid and mixed with 0.24 ml of 67% hydroiodic acid (0 , 32 g = 2.5 mmol hydrogen iodide) are added, a precipitate gradually forming. It is left to stand at 20 ° C. overnight and then heated to 60 ° C. for 5 hours.
Aqueous sodium thiosulphate solution is added to the reaction mixture to remove iodine and it is extracted with chloroform. After washing the organic extract with dilute sodium hydroxide solution, dilute hydrochloric acid and what water, it is dried and evaporated in vacuo. Column chromatography on silica gel (benzone / acetone = 3: 1) allows 30 mg (77% of theory) of colorless crystals with a melting point of 130 to 133 ° C. to be isolated.
<I> Example 2 </I> 4-Bromo-cinnamic acid piperidide A mixture of 1.0 g (2.4 mmol) α, ss-diacetoxy-ss- (4-bromophenyl) -propionic acid piperidide (m.p. 92 to 93 C, prepared from α, ß-dihydroxy-ss- (4-bromophenyl) -propionic acid piperidide and acetic anhydride in the presence of pyridine), 0.46 ml of 67% aqueous hydroiodic acid (0.62 g = 4.8 mmoles of hydrogen iodide ) and 20 ml of glacial acetic acid are left to stand at 20 ° C. for 20 hours and then heated to 40 ° C. for a further 5 hours. A few ml of aqueous sodium thiosulfate solution are added and the mixture is extracted with chloroform.
The chloroform phase is washed with dilute sodium hydroxide solution, dilute hydrochloric acid and water and, after drying, evaporated in vacuo. The residue is separated by column chromatography on silica gel (benzene / acetone = 9: 1), 100 mg (14% of theory) of 4-bromocinnamic acid piperidide of melting point 132 to 133 ° C. being obtained .
<I> Example 3 </I> 4-Bromo-cinnamic acid piperidide 1.3 g (2 mmol α, ss-di- (p-toluenesulfonyloxy) -ss- (4-bromophenyl) -propionic acid piperidide (m.p. 150 to 151 C, made from a, ss-dihydroxy-ss- (4-bromopheny) -propionic acid piperidide and p-toluene sulfochloride in the presence of pyridine) and 1.8 g (12 mmol) of sodium iodide are dissolved in 50 ml of methyl ethyl ketone 16 Hours at 80 ° C. The iodine formed is reduced by shaking with aqueous sodium thiosulphate solution.
It is evaporated in vacuo, chloroform and water are added to the residue, the chloroform phase is separated off in a separating funnel, washed with dilute sodium hydroxide solution, dilute hydrochloric acid and water, dried over sodium sulfate and the solvent is removed in vacuo. The back sand is recrystallized from Es sigester using activated carbon. Yield: 0.45 g (76% of theory), melting point 132 to 133 C.
The following connections were made in the same way:
EMI0002.0019
3-bromo-cinnamic acid piperidide, <SEP> m.p. <SEP> 95 <SEP> - <SEP> 99 C
<tb> 4-Bromo-cinnamic acid morpholide, <SEP> mp. <SEP> 142 <SEP> - <SEP> 144 C
<tb> 3-Bromo-cinnamic acid morpholide, <SEP> melting point <SEP> 80 <SEP> - <SEP> 81 C
<tb> 4-iodo-cinnamic acid piperidide, <SEP> mp. <SEP> 134 <SEP> - <SEP> 135 C
<tb> 3-iodo-cinnamic acid piperidide, <SEP> mp. <SEP> 109 <SEP> - <SEP> 110 C
<tb> 4-iodo-cinnamic acid morpholide, <SEP> melting point <SEP> 175 <SEP> - <SEP> 177 C
<tb> 3-iodocinnamic acid morpholide, <SEP> melting point <SEP> 100 <SEP> - <SEP> 101 C The compounds of the formula I prepared according to the invention can be converted into customary pharmaceutical application forms by methods known per se, if necessary in combination with other active ingredients.
The single dose for adults is 200.00 mg to 600.00 mg, preferably 300.00 mg to 400.00 mg and the daily dose 400.00 mg to 1 200.00 mg, preferably 600.00 mg to 800.00 mg.
Claims (1)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT1091167A AT280283B (en) | 1967-12-01 | 1967-12-01 | Process for the preparation of new cinnamic acid amides |
AT1075768A AT285606B (en) | 1968-11-05 | 1968-11-05 | Process for the production of new cinnamic acid amides |
AT1075568A AT281821B (en) | 1968-11-05 | 1968-11-05 | Process for the production of new cinnamic acid amides |
CH343471A CH516554A (en) | 1968-11-05 | 1968-11-29 | Process for the production of new cinnamic acid amides |
Publications (1)
Publication Number | Publication Date |
---|---|
CH516557A true CH516557A (en) | 1971-12-15 |
Family
ID=27422296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH1442871A CH516557A (en) | 1967-12-01 | 1968-11-29 | Antiphlogistic cinnamamides |
Country Status (1)
Country | Link |
---|---|
CH (1) | CH516557A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4283404A (en) * | 1979-09-04 | 1981-08-11 | Richardson-Merrell Inc. | Aroylethenylpiperidinobutyrophenone antipsychotic agents |
US4284636A (en) | 1979-09-04 | 1981-08-18 | Richardson-Merrell Inc. | Cinnamoylpiperidinobutyrophenone antipsychotic agents |
-
1968
- 1968-11-29 CH CH1442871A patent/CH516557A/en not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4283404A (en) * | 1979-09-04 | 1981-08-11 | Richardson-Merrell Inc. | Aroylethenylpiperidinobutyrophenone antipsychotic agents |
US4284636A (en) | 1979-09-04 | 1981-08-18 | Richardson-Merrell Inc. | Cinnamoylpiperidinobutyrophenone antipsychotic agents |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3042466A1 (en) | N-SUBSTITUTED (OMEGA) - (2-OXO-4-IMIDAZOLIN-L-YL) -ALKANIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | |
CH516557A (en) | Antiphlogistic cinnamamides | |
AT202152B (en) | Process for the preparation of new dimethylaminopropylidene thiaxanthenes. | |
CH498135A (en) | Pharmaceutical furazan derivs prodn | |
US3354206A (en) | 10, 11-dihydro-5-hydroxy-5-vinyl-5h-dibenzo-[a, d] cycloheptenes | |
AT283364B (en) | Process for the production of new cinnamic acid amides | |
AT283365B (en) | Process for the production of new cinnamic acid amides | |
AT282629B (en) | PROCESS FOR PREPARING NEW CINNAMID AMIDES | |
AT344687B (en) | METHOD FOR MANUFACTURING NEW ALDEHYDOLACTONE | |
AT346838B (en) | PROCESS FOR MANUFACTURING NEW OPTICALLY ACTIVE ANTHRACYCLINONES | |
CH516555A (en) | Process for the production of new cinnamic acid amides | |
AT288399B (en) | Process for the preparation of new cinnamic acid amides | |
US2621190A (en) | Process for producing conjugated steroids | |
AT214437B (en) | Process for the production of partially hydrogenated anthracene derivatives | |
CH444850A (en) | Process for the preparation of 5H-dibenzo (a, d) cycloheptenes | |
AT282630B (en) | Process for the production of new cinnamic acid amides | |
AT283366B (en) | Process for the production of new cinnamic acid amides | |
AT353253B (en) | PROCESS FOR THE PRODUCTION OF NEW PHENOXY ACETIC ACID DERIVATIVES | |
AT214582B (en) | Process for the preparation of 3β-hydroxy- or 3β-acyloxy-6-methyl-25D-spirost-5-ene | |
AT238380B (en) | Process for the preparation of 9 (11), 16-pregnadienes | |
DE2102623A1 (en) | ||
DE1620248A1 (en) | Dihydro-pyrolysis base B and process for their preparation | |
CH510019A (en) | Antiphlogistic, antipyretic halo-cinnama-mides | |
DE3100968A1 (en) | Anthracycline derivatives, a process for their preparation and pharmaceuticals containing these compounds | |
CH402844A (en) | Process for the production of new sulfonamides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PL | Patent ceased |